1 The EIC Accelerator Project
The European Innovation Council (EIC) Accelerator program is a flagship funding initiative designed to support innovative small and medium-sized enterprises (SMEs), particularly those operating in the DeepTech sector. The program aims to foster groundbreaking technologies and business models that have the potential to significantly impact the European economy and society. By providing both grant funding and equity investments, the EIC Accelerator serves as a vital resource for startups aiming to scale their operations and navigate the complex landscape of private sector financing.Funding Structure of the EIC Accelerator
The EIC Accelerator offers a unique funding mechanism that combines both grants and equity investments. The grant component can provide up to €2.5 million to cover the costs associated with innovative projects, including research and development, prototyping, and market entry strategies. This non-repayable funding is particularly advantageous for companies in their early stages, allowing them to advance their technologies without the immediate pressure of repayment.
In addition to grants, the EIC Accelerator offers equity investments that range up to €15 million until 2024 and subsequently up to €10 million starting in 2025. This equity financing is intended to support companies in scaling their operations and achieving market traction. The investment is designed to attract further private sector funding, thereby amplifying the impact of the initial public investment.
Purpose and Impact on the European DeepTech Ecosystem
The EIC Accelerator plays a pivotal role in the European DeepTech and startup ecosystem by bridging the funding gap that often exists for innovative SMEs. Many startups struggle to secure financing from traditional private investors due to their high-risk profiles and the long timelines associated with DeepTech development. The EIC Accelerator addresses this challenge by providing a reliable source of funding that validates the technological and commercial viability of these enterprises.
By supporting startups in their scaling efforts, the EIC Accelerator fosters innovation, drives job creation, and enhances the competitiveness of European businesses on a global scale. The program also emphasizes the importance of sustainability and societal impact, aligning with broader European Union objectives.
Case Study: PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIA
Project Overview
One notable winner of the EIC Accelerator is PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIA, a Greek company that submitted a proposal for their project titled "Laser bioprinting device and in vivo applications" on June 15, 2022. This project is at the forefront of bioprinting technology, which has significant implications for fields such as regenerative medicine, drug testing, and tissue engineering.
Technology Background
The laser bioprinting device developed by PHOSPRINT utilizes advanced laser technology to precisely deposit living cells and biomaterials layer by layer, creating complex three-dimensional tissue structures. This innovative approach allows for high-resolution printing of biological materials, making it possible to construct tissues that closely mimic natural structures.
The technology operates by using a laser to create a focused energy beam that can manipulate cells without contact, preserving their viability and functionality. This method contrasts with traditional bioprinting techniques that often rely on mechanical or pneumatic systems, which can damage delicate cells during the printing process.
The in vivo applications of this technology aim to extend its utility beyond laboratory settings, enabling the creation of implantable tissues that can integrate seamlessly with living organisms. This has profound implications for personalized medicine, allowing for the development of patient-specific tissue grafts that can be used in surgical procedures.
Conclusion
The EIC Accelerator serves as a crucial pillar in the European innovation landscape, particularly for DeepTech startups like PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIA. By providing substantial funding and support, the program not only facilitates the development of groundbreaking technologies such as the laser bioprinting device but also enhances the overall capacity of the European economy to innovate and compete on a global scale. Through initiatives like these, the EIC Accelerator fosters a vibrant ecosystem that nurtures the next generation of technological advancements.
2 The Funding Rounds
PhosPrint IDIOTIKI KEFALAIOUXIKIETAIREIA (PhosPrint) — Funding and Financing Overview
Financing Raised & Funding Rounds
PhosPrint, a Greek deep-tech spin-off specializing in laser bioprinting for biomedical applications, has participated in several funding rounds since its inception:
- The earliest recorded funding activity dates to January 2019; however, the disclosed amount for this round is listed as $0.0, suggesting either a non-equity event or undisclosed terms.
- In June 2022, coinciding with their successful application to the EIC Accelerator program (cut-off date June 15, 2022), PhosPrint was selected for grant and equity support under the European Innovation Council (EIC) Accelerator scheme. The specific amount raised through this EIC Accelerator round is not publicly disclosed on mainstream databases but typically includes up to €2.5 million in grants and up to €15 million in equity per standard EIC Accelerator guidelines.
Timing and Amount of Funding Rounds
- January 2019: Initial round with no public disclosure of raised capital.
- June 2022: Selected for EIC Accelerator funding — precise figures not published but standard EIC awards apply (grant + potential equity).
Investor Information
The main known investor is the European Innovation Council (EIC) through its highly competitive Accelerator program. There are no other disclosed institutional or venture investors listed in available sources post-EIC award. Additionally:
Company Valuations
No explicit company valuation figures have been made public following any of PhosPrint's known financing events. As valuations are often tied to large private equity rounds or IPOs—and given that neither event appears on record—no formal valuation data exists within current sources.
Exit Events: IPOs or Buyouts/Acquisitions
There are no records indicating that PhosPrint has undergone an IPO, buyout, or acquisition since winning its EIC Accelerator grant. No exit events have been reported as of May 2025 across industry trackers and investor databases referencing the company’s financial history.
Summary Table
| Date | Round/Funding Type | Amount Raised | Main Investor(s) | Exit Event |
|---|---|---|---|---|
| Jan 2019 | Early/Undisclosed | Not Disclosed | Not Publicly Listed | None |
| Jun 2022 | EIC Accelerator Grant | Not Disclosed | European Innovation Council (EIC) | None |
</em>Typical maximums per standard program rules.
Sources
- PhosPrint company information, funding & investors - Dealroom.co
- PhosPrint is funded by the European Innovation Council Accelerator
- Ownership & Structure - PhosPrint
- PhosPrint company information, funding - Finder Techleap.nl
- PhosPrint company information, funding & investors - Sao Paulo Dealroom
3 The Press Releases
PhosPrint: Laser Bioprinting Pioneer and 2022 EIC Accelerator Winner PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIA (PhosPrint), a Greek deep-tech company specializing in laser bioprinting, secured EIC Accelerator funding in the June 15, 2022 cut-off. The company’s winning proposal focused on its dual-beam laser bioprinting device and surgical protocols for autologous cell transplantation, aiming to revolutionize bladder reconstruction post-cancer surgery.Key Developments Post-EIC Funding
- Technology Advancements: PhosPrint’s device enables precise delivery of cells and bio-inks for tissue regeneration, targeting conditions like bladder cancer. Their approach replaces traditional cystoplasty methods that rely on intestinal tissue, reducing complications.
- Project Milestones: The EIC-funded project (ID: 190195672) advances microfluidics, cell biology, and surgical protocols. A related Horizon Europe project (LIBRA) focuses on pathogen detection in bioreactors.
- Awards & Recognition: In December 2024, PhosPrint was named a MedTech finalist at the Tech Gala Awards 2024 by EISMEA and WLOUNGE. CEO Ioanna Zergioti highlighted pre-clinical trial completions and new collaborations during media appearances.
Recent Updates
- Pre-clinical Progress: As of late 2024, preclinical trials for bladder reconstruction applications were finalized.
- Public Engagement: PhosPrint actively showcases its technology at industry events and through media outreach, including interviews with Naftemporiki TV.
Sources
4 The Technology Advancements
PhosPrint IKE: Advancements and Progress
PhosPrint IKE, a Greek company specializing in laser bioprinting technology, has made significant strides since receiving funding from the European Innovation Council (EIC) Accelerator in June 2022.
Current Capabilities
PhosPrint focuses on developing high-precision laser bioprinters for the rapid delivery of cells and bio-inks onto substrates. Their technology allows for precise cell placement with high resolution, making it suitable for complex tissue architectures. The company's Dual Beam I bioprinter is equipped with features such as dual wavelength modules, temperature control, and UV LED and HEPA filters for contamination control. It supports printing volumes from picoliters to nanoliters and offers real-time process monitoring.
Advancements Since EIC Funding
Following the EIC Accelerator funding, PhosPrint has continued to advance its technology. The company has successfully completed pre-clinical trials and has been recognized as a finalist in the MedTech category at the prestigious Tech Gala Awards 2024. This recognition highlights PhosPrint's innovative approach to bioprinting, particularly in tissue regeneration applications.
Technology Demonstrations and Clinical Trials
PhosPrint has showcased its technology at key events and forums, demonstrating its potential for in-vivo applications, such as bladder tissue repair. The company's D-LIB platform is designed for high-speed and high-precision tissue printing, aiming to introduce laser bioprinting into surgical procedures.
Patents and Scientific Publications
While specific details on new patent filings or scientific publications since the EIC funding are not readily available, PhosPrint's intellectual property registration has been supported by several foundations, indicating ongoing efforts to protect their innovations. There is no public information on recent clinical trials or whitepapers specifically attributed to PhosPrint.
Market Presence
PhosPrint's participation in prominent events like the Tech Gala Awards and its presence at MEDICA highlight its efforts to establish a market presence and engage with potential customers and partners.
Conclusion
PhosPrint IKE has made notable progress since receiving EIC funding, focusing on refining its laser bioprinting technology and demonstrating its potential in pre-clinical settings. The company continues to innovate and expand its reach in the regenerative medicine sector.
Sources: - PhosPrint, Laser Bioprinter
- Ownership & Structure - PhosPrint
- Technology & Products - PhosPrint
- About us - PhosPrint
- PhosPrint is funded by the European Innovation Council Accelerator
- Laser bioprinting device and in vivo applications
- PhosPrint IKE PC - MEDICA
5 The Partnerships and Customers
PhosPrint Partnerships and Market Positioning PhosPrint IDIOTIKI KEFALAIOUXIKIETAIREIA, a Greek laser bioprinting pioneer and EIC Accelerator grant recipient (€2 million secured in 2024), has strategically aligned with academic, clinical, and technological partners to advance its regenerative medicine solutions. While specific customer names remain undisclosed, the company’s collaborative projects and affiliations highlight its market trajectory.Key Partnerships
- EIC Accelerator: The funding supports pre-clinical trials and commercialization of their dual-beam laser bioprinter for in vivo cell printing during surgeries.
- LIBRA Project: Participates in Horizon Europe’s light-based multisensing initiative for bioreactor pathogen detection, enhancing cross-sectoral expertise in photonics and microfluidics.
- Tumor-LN-oC Consortium: Collaborates on tumor-lymph node-on-chip models under H2020 NMBP-23-2020, integrating laser printing with immunocompatible tissue engineering.
- Advisory Network: Includes MDs, regenerative medicine experts (e.g., Dr. Achilleas Gravanis), and MedTech executives advising on clinical translation.
Market Positioning through Relationships
These partnerships solidify PhosPrint’s role as a leader in precision bioprinting for surgical applications. By aligning with EU-funded consortia like LIBRA and Tumor-LN-oC, the company gains access to multidisciplinary R&D ecosystems—accelerating technology validation for regulatory approval (targeting first-in-human trials post-preclinical success). The EIB’s conditional funding commitment further de-risks scaling efforts ahead of planned 2028 commercialization.Technological Advancements
Collaborations enable:Sources
6 The Hiring and Company Growth
PhosPrint's Organizational Growth and Team Dynamics Post-EIC Accelerator Funding PhosPrint Idiotiki Kefalaiouxikietaireia, a Greek SME specializing in laser bioprinting for surgical applications, secured EIC Accelerator funding under the Horizon Europe program in 2022. While specific headcount figures and hiring timelines are not publicly disclosed, the company’s project documentation and public records provide insights into its operational trajectory.Team Expansion and Strategic Hiring
The company’s D-LIB platform, developed for in vivo tissue printing during surgical procedures, emphasizes automation and precision. This suggests a reliance on multidisciplinary teams combining expertise in laser physics, biomedical engineering, and clinical oncology. Although exact team size remains unspecified, participation in Horizon Europe projects typically necessitates scaling technical and operational roles to meet R&D milestones.- Key Positions: PhosPrint likely prioritizes roles such as:
- Biomedical engineers for tissue protocol development.
- Laser systems specialists to refine its LIFT-based bioprinter.
- Clinical liaisons to bridge surgical integration (cited under "go-to-market applications" for bladder cancer patients).
Growth Trajectory Post-Funding
The EIC Accelerator’s blended finance model supports commercialization efforts, implying team growth to address:- Regulatory compliance for medical devices.
- Market entry strategies for its target application (enterocystoplasty/augmentation).
Management Stability
No leadership changes are documented since the 2022 funding round. As an SME, PhosPrint likely retains its original management structure while expanding specialized technical roles to advance its D-LIB platform toward clinical adoption.Sources
- Laser bioprinting device and in vivo applications | CORDIS
- Photonics21 Multi-annual Strategic Roadmap 2023–2030
7 The Media Features and Publications
PhosPrint IDIOTIKI KEFALAIOUXIKIETAIREIA: Media, Events, and Public Engagement As a Greek EIC Accelerator winner (2022), PhosPrint has actively engaged in conferences, media interviews, and public events to showcase its laser bioprinting innovations. Below is a detailed overview of its visibility since securing Horizon Europe funding.Media Features & Publications
While specific third-party publications are not explicitly listed in available materials, the company’s website highlights press releases and media coverage, including CEO Dr. Ioanna Zergioti’s December 2024 interview on Naftemporiki TV with Takis Spiliopoulos. The interview marked the conclusion of a pivotal year for PhosPrint, emphasizing milestones such as pre-clinical trial completions and technology demonstrations.Podcasts & Interviews
- CEO Spotlight: Dr. Zergioti participated in a panel discussion at the “Female Startup Founders: Funding Innovative Investments” event (February 2025), organized by ICC Women Hellas alongside Ministers Niki Kerameus and Zoe Rapti. While not a podcast, this high-profile event underscores her role as a key voice in Greece’s biotech startup ecosystem.
- Corporate Updates: The company regularly shares progress through its website’s news section, though no standalone podcasts have been documented publicly.
Conferences & Fairs
- EIC Affiliation: As an EIC Accelerator grant recipient under Horizon Europe (Project ID: 190195672), PhosPrint participates indirectly in EU innovation networks. Its D-LIB bioprinter project focuses on surgical applications for bladder cancer patients.
- [UroPrint Consortium]: Although not directly named as an organizer or participant beyond its own projects, PhosPrint’s foundational LIFT bioprinting methodology aligns with collaborative initiatives like UroPrint (EU Project ID: 964883).
Event Involvement
- February 2025 Panel: Dr. Zergioti joined female founders and investors at the ICC Women Hellas event to discuss funding challenges and innovation strategies.
- Technology Showcases: Pre-clinical trial results were presented at unspecified forums during 2024–2025 per annual summaries.
Sources
- Phosprint Official Website – News and contact details
- CORDIS Project Details – EIC Accelerator grant summary
- UroPrint Bladder Bioprinting Initiative – Collaborative research context
Note: Specific third-party articles or podcasts are not cited here due to limited publicly indexed mentions.
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.